MPMaria Augusta Pacheco

Maria Augusta Pacheco

*This is an algorithmically generated author record based on publicly available information.

Maria Augusta Pacheco has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Adults philadelphia-positive B–acute lymphoblastic leukemia in a moderate health access and quality index Country

    by Jairo Quinonez, Brenner Sabando, Andres Orquera, Danilo Navarrete, Jhoanna Ramirez, Maria Augusta Pacheco, Jhonny Carranza, Venus Rodriguez, Noor Shaban

    Aims: to describe clinical and demographic characteristics, as well as to evaluate response and survival outcomes in Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) Ecuadorian adults. Methods: A retrospective, multicenter cohort study in patients aged >15 years diagnosed with Ph+ B-cell ALL was carried out. Diagnosis of B-ALL was established based on 2016 WHO classification and Ph+ mutation was confirmed in all cases. Results: 61 (12.4%) were identified with Ph+ chromosome. 56 were included in the analysis, 33 (58.9%) were male, and median age was 40.5 years [interquartile range (IQR): 25–51; range: 16–85]. 46 (82.1%) subjects were treated with Imatinib. CR was achieved in 30 (53.6%) patients. MRD was reported in 13/41 (31.7%). Only 5/29 eligible patients underwent HSCT. 9 (16.1) died in induction phase, all deaths were attributed to bacterial infections. Relapse was recorded in 7 (12.5%). Median OS for total cohort was 11 months (95% CI 8.1–13.9), with a 5-year OS of 26.8%. Imatinib therapy [HR 0.44 (95% CI 0.19 – 0.98); p=0.046]; Imatinib 800mg dose [HR 0.30 (95% CI 0.11 – 0.83); p=0.020]; Hyper-CVAD protocol [HR 0.44 (95% CI 0.21 – 0.93); p=0.031] were associated to better OS. Conclusion: Response and survival outcomes in Ecuadorian population are poorer compared to high income countries caused by high rate of induction death, low availability of MRD monitoring, lack of standardization of treatment protocols, restricted access to HSCT, and delayed initiation to TKIs therapy.

  • Open Access

    Hyper‐CVAD in Adults With Acute Lymphoblastic Leukemia in Ecuador: A Multicenter Retrospective Study

    by Brenner Sabando, Jairo Quinonez, Andrés Orquera, Danilo Navarrete, Jhoanna Ramírez, Lorena Sanchez, Teodoro Chisesi, Jorge Oliveros, María A. Pacheco, María C. Trujillo, et al.

    Background: The Hyper‐CVAD protocol is a chemotherapy regimen widely used in hematological malignancies. It is considered one of most promising remission‐leading treatment option for adults with acute lymphoblastic leukemia (ALL). Objective: To determine the outcomes of adults with ALL treated with the Hyper‐CVAD protocol in Ecuador. Methods: This multicenter, retrospective, cross‐sectional study compared the outcomes of ALL patients aged 15 years and older treated with hyper‐CVAD protocol in 8 specialized centers. Results: 139 patients with ALL treated with the Hyper‐CVAD protocol were included. A total of 79 were female (56.8%) and the majority had a B‐type phenotype 130 (93.5%). A complete response (CR) was achieved in 64.3%. Relapse was confirmed in 52.7% of those who obtained CR. Negative minimal residual disease (MRD) was achieved in 20% of patients. The median overall survival (OS) was 11 months (95% CI: 7.49–14.50) with a 5‐year OS of 14.0%. A total of 12 (8.6%) deceased during induction phase. Conclusion: Adult patients treated with the Hyper‐CVAD protocol in Ecuador achieve rates of CR, MRD, and OS lower than those presented in international cohorts, as well as higher rates of treatment‐related toxicity.